MJR PharmJet GmbH

News

The European Commission grants “npSCOPE” project bringing together nine partners including MJR PharmJet to develop a new integrated instrument for accurate and reproducible physicochemical characterisation of nanoparticles as part of the “H2020-NMBP: CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION” program. The npSCOPE project aims at developing a new integrated instrument (the nanoparticle-scope) optimised for providing a complete physico-chemical characterisation of nanoparticles both in their pristine form or embedded in complex matrices such as biological tissues. Using sophisticated correlative data processing methodologies and algorithms based on statistical methods in conjunction with appropriate visualisation methods of the results, the npSCOPE instrument will allow rapid, accurate and reproducible measurements.

For more information: www.npscope.eu/

CPhI Worldwide, organised by UBM Live, announced the winners of the 11th annual CPhI live Pharma Awards. The annual awards showcase outstanding developments and innovations from the pharma industry's most dynamic and progressive players. Open to the entire pharma industry, the awards honour companies that are driving the industry forward with thought leadership, unveiling top pharma innovators to global trade. In addition to returning annual award categories for 'Formulation', 'Process Development' and 'Packaging', a new category recognising 'Innovation in Partnering' debuts this year. Supported by Pharmaceutical Outsourcing magazine, this award honours partnering methods, use of technology, unexpected outcomes and unique partnering practices.

The awards panel deliberated for several hours over the impressive list of entries, before coming to the unanimous decision, selecting MJR PharmJet in the Formulation category:

By forming counter-ion complexes, the solubility of the API can be improved without chemically altering it, allowing nanoparticles with an enhanced load to be formed via the company's microjet technology. The principle has been proved via a formulation of the drug ciprofloxacin for cystic fibrosis patients, creating a nanodelivery system that allows the drug to penetrate the thick mucus that forms in their lungs. The employed technology can be applied to a wide range of molecules and different markets, including nutraceuticals and cosmetics. 

MJR PharmJet participates in the European research project “N2B-Patch” project financed by the European Commision for the call “H2020-NMBP: CALL FOR NANOTECHNOLOGIES, ADVANCED MATERIALS, BIOTECHNOLOGY AND PRODUCTION” program. The N2B-Patch project brings Universities, Research institutes, SMEs and Industry with complementary distinct expertise out of chemical, biological, regulatory and business areas. Project aims to  develop a new innovative nose to brain drug delivery technology based on the synthesis of a biomaterial-based innovative galenic formulation that will be applied with the aid of a novel medical device equipped with a container closure system as a hydrogel patch to the nasal olfactory region for the chronic treatment of MS. 

Click here for N2B-Patch press release

 

The 2015 Gips-Schüle Research Award in the amount of EUR 50,000 goes to the research project “Nanoparticles for the Environmentally Compatible Production of Organic Solar Cells” of Karlsruhe Institute of Technology (KIT) in cooperation with MJR PharmJet GmbH. The project in which engineers, physicists, chemists, and biologists cooperate is aimed at developing low-cost methods for the production of new solar cells without any solvents that are harmful to human health.

“Photovoltaics is a major component of electricity supply based on renewable sources. Current growth rates suggest that its relevance will significantly increase in the future. Hence, it is very important to use “green” technologies for production already,” the President of KIT, Professor Holger Hanselka, says. “The novel process developed by KIT in cooperation with industry is not only highly innovative, but also sustainable and inexpensive. The Gips-Schüle Research Award is a wonderful recognition of this great achievement.” 

MJR PharmJet`s  Soapbox application has been accepted for presentation at the 2015 CRS Annual Meeting & Exposition held in Edinburgh, Scotland. Soapbox sessions of the Annual CRS Meetings are well-attended, highly interactive part of the program giving an opportunity companies to present new ideas, products and services. CRS official website reports that Soapbox sessions attract attendees from “Big Pharma, biotechs, product formulators, licensing officers, venture capitalists, technology transfer offices, universities—in essence, anyone and everyone who has an interest in exploring the hottest innovations and tools”. MJR PharmJet was selected among a huge number of applicants with proposed presentation titled “ Microjet Reactor Technology for Continuous Nanoparticle Production under Controlled Conditions”. 

MJR PharmJet moved to its new premises in Überherrn, Saarland under the structure of Instillo Group. Überherrn is in the triangle of Germany, France and Luxembourg. It is well connected with high ways and two international airports (Luxembourg and Frankfurt) and a regional one (Saarbrücken). The new premises has a lab capacity of 1000 m2, 500 mtechnical rooms and 350 m2 offices. Smart energy systems is integrated in the new buildings with photovoltaic arrays, block heat and power plant. Furthermore MJR PharmJet further strengthen development competence with the other members of the Instillo group, Quasaar and Nanosaar. Target investment of Instillo group to new promises is over 10 Mio Euro with in next 3 years with a provision of 70-80 new jobs.